Ten Open Questions in Migraine Prophylaxis with Monoclonal Antibodies Blocking the Calcitonin-gene Related Peptide Pathway: a Narrative Review

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2023 Aug 1

PMID 37528353

Authors

Jean Schoenen

Annelies Van Dycke

Jan Versijpt

Koen Paemeleire

Affiliations

Soon will be listed here.

Abstract

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP) pathway, collectively called here "anti-CGRP/rec mAbs", have dramatically improved preventive migraine treatment. Although their efficacy and tolerability were proven in a number of randomized controlled trials (RCTs) and, maybe even more convincingly, in real world settings, a number of open questions remain. In this narrative review, we will analyze published data allowing insight in some of the uncertainties related to the use of anti-CGRP/rec mAbs in clinical practice: their differential efficacy in migraine subtypes, outcome predictors, switching between molecules, use in children and adolescents, long-term treatment adherence and persistence, effect persistence after discontinuation, combined treatment with botulinum toxin or gepants, added-value and cost effectiveness, effectiveness in other headache types, and potential contraindications based on known physiological effects of CGRP. While recent studies have already provided hints for some of these questions, many of them will not find reliable and definitive answers before larger studies, registries or dedicated RCTs are available.

Citing Articles

A case of sporadic hemiplegic migraine treated with eptinezumab: should we consider anti-CGRP antibodies for selected patients?.

Antenucci P, Pes F, Cesnik E, Capone J, Padroni M Neurol Sci. 2025; .

PMID: 39745588 DOI: 10.1007/s10072-024-07980-0.

Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb).

Seng E, Lampl C, Viktrup L, Lenderking W, Karn H, Hoyt M Pain Ther. 2024; 13(6):1589-1615.

PMID: 39298053 PMC: 11543966. DOI: 10.1007/s40122-024-00652-z.

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.

Della Vecchia A, De Luca C, Becattini L, Curto L, Ferrari E, Siciliano G Biomedicines. 2024; 12(3).

PMID: 38540290 PMC: 10968025. DOI: 10.3390/biomedicines12030677.

Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics.

Jankovic S, Jankovic S Eur J Drug Metab Pharmacokinet. 2024; 49(3):277-293.

PMID: 38461486 DOI: 10.1007/s13318-024-00885-5.

Atogepant: Mechanism of action, clinical and translational science.

Boinpally R, Shebley M, Trugman J Clin Transl Sci. 2024; 17(1):e13707.

PMID: 38266063 PMC: 10777605. DOI: 10.1111/cts.13707.

References

Vig S, Garza J, Tao Y . The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache. 2022; 62(10):1256-1263. DOI: 10.1111/head.14305. View

Cullum C, Do T, Ashina M, Bendtsen L, Hugger S, Iljazi A . Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022; 23(1):61. PMC: 9164431. DOI: 10.1186/s10194-022-01433-9. View

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

Benschop R, Collins E, Darling R, Allan B, Leung D, Conner E . Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014; 22(4):578-85. DOI: 10.1016/j.joca.2014.01.009. View

Sessa M, Andersen M . New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs. 2021; 35(2):215-227. DOI: 10.1007/s40259-021-00469-8. View

Wang X, Chen Y, Song J, You C . Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Front Pharmacol. 2021; 12:649143. PMC: 8045977. DOI: 10.3389/fphar.2021.649143. View

Giannouchos T, Mitsikostas D, Ohsfeldt R, Vozikis A, Koufopoulou P . Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece. Clin Drug Investig. 2019; 39(10):979-990. DOI: 10.1007/s40261-019-00827-z. View

Yiangou A, Mitchell J, Fisher C, Edwards J, Vijay V, Alimajstorovic Z . Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation. Headache. 2020; 61(1):157-169. PMC: 7898289. DOI: 10.1111/head.14026. View

10.

de Vries Lentsch S, Garrelds I, Danser A, Terwindt G, MaassenVanDenBrink A . Serum CGRP in migraine patients using erenumab as preventive treatment. J Headache Pain. 2022; 23(1):120. PMC: 9464612. DOI: 10.1186/s10194-022-01483-z. View

11.

Visocnik D, Zaletel M, Zvan B, Zupan M . The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine. Front Neurol. 2022; 13:854134. PMC: 9160185. DOI: 10.3389/fneur.2022.854134. View

12.

Goadsby P, Dodick D, Leone M, Bardos J, Oakes T, Millen B . Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med. 2019; 381(2):132-141. DOI: 10.1056/NEJMoa1813440. View

13.

Mathew N, Kurman R, Perez F . Drug induced refractory headache--clinical features and management. Headache. 1990; 30(10):634-8. DOI: 10.1111/j.1526-4610.1990.hed3010634.x. View

14.

Sacco S, Amin F, Ashina M, Bendtsen L, Deligianni C, Gil-Gouveia R . European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022; 23(1):67. PMC: 9188162. DOI: 10.1186/s10194-022-01431-x. View

15.

Giri S, Tronvik E, Linde M, Pedersen S, Hagen K . Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia. 2023; 43(4):3331024231156922. DOI: 10.1177/03331024231156922. View

16.

Aradi S, Kaiser E, Cucchiara B . Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report. J Stroke Cerebrovasc Dis. 2019; 28(10):104286. DOI: 10.1016/j.jstrokecerebrovasdis.2019.07.002. View

17.

Lipton R, Buse D, Sandoe C, Ford J, Hand A, Jedynak J . Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. Headache. 2023; 63(5):683-691. DOI: 10.1111/head.14460. View

18.

Eigenbrodt A, Ashina H, Khan S, Diener H, Mitsikostas D, Sinclair A . Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021; 17(8):501-514. PMC: 8321897. DOI: 10.1038/s41582-021-00509-5. View

19.

Deng H, Li G, Nie H, Feng Y, Guo G, Guo W . Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol. 2020; 20(1):57. PMC: 7023812. DOI: 10.1186/s12883-020-01633-3. View

20.

Schoenen J, Snoer A, Brandt R, Fronczek R, Wei D, Chung C . Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache. Cephalalgia. 2022; 42(14):1450-1466. DOI: 10.1177/03331024221120266. View